Is Repligen Corporation overvalued?

Repligen Corporation (RGEN) looks overvalued — trading about 59% above its fair value.

Overvalued

Price

$167.23

Fair value

$68.19

Current P/E

92.9

Normal P/E

37.9

Market cap

$9.44B

Dividend yield

0.0%

Return on equity

2.0%

Sector

Healthcare

Fair value compares RGEN's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 11 Aug 2026.

Related stocks